肿瘤突变负荷在肝癌中的应用进展
Advances in the Application of Tumor Mutation Burden in Hepatocellular Carcinoma
摘要: 肝细胞肝癌(Hepatocellular carcinoma, HCC)作为一种常见的消化系统恶性肿瘤，预后较差。肿瘤突变负荷(Tumor Mutational Burden, TMB)是指编码区的体细胞非同义突变的总数，表示为肿瘤中每兆碱基的突变(突变/Metabase，突变/Mb)。关于基因突变及肿瘤突变负荷的研究在肝癌的发生发展中能为预后、治疗等方面提供进一步指导。作为新兴治疗评价及肿瘤预后的生物学标志物之一，本文就TMB在肝细胞肝癌患者的免疫治疗疗效中的预测价值、预后价值、肿瘤微环境及应用进展等方面进行综述。
Abstract: Hepatocellular carcinoma (HCC) is a common malignant tumor of digestive system with poor prognosis. Tumor mutational burden (TMB) refers to the total number of non-synonymous mutations in the coding region of the somatic cells, which is expressed as mutations per Megabyte in the tumor (mutation/Mb). The study of gene mutation and tumor mutational burden can provide further guidance for the prognosis and treatment of HCC. As one of the biomarkers for the evaluation of emerging therapies and the prognosis of tumors, this paper reviewed the predictive value, prognostic value, tumor microenvironment and application progress of TMB in the therapeutic effect of immunotherapy for HCC patients.
文章引用：张爱绮, 龚建平. 肿瘤突变负荷在肝癌中的应用进展[J]. 临床医学进展, 2022, 12(3): 1724-1729. https://doi.org/10.12677/ACM.2022.123248

参考文献

[1] Islami, F., Ward, E.M., Sung, H., et al. (2021) Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics. JNCI: Journal of the National Cancer Institute, 113, 1648-1669. [Google Scholar] [CrossRef] [PubMed]
[2] Yarchoan, M., Hopkins, A. and Jaffee, E.M. (2017) Tumor Mutational Burden and Response Rate to PD-1 Inhibition. The New England Journal of Medicine, 377, 2500-2501. [Google Scholar] [CrossRef] 
[3] Klempner, S.J., Fabrizio, D., Bane, S., et al. (2020) Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. The Oncologist, 25, e147-e159. [Google Scholar] [CrossRef] [PubMed]
[4] Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. [Google Scholar] [CrossRef] [PubMed]
[5] Van Den Bulk, J., Verdegaal, E.M. and De Miranda, N.F. (2018) Cancer Immunotherapy: Broadening the Scope of Targetable Tumours. Open Biology, 8, Article ID: 180037. [Google Scholar] [CrossRef] [PubMed]
[6] Merino, D.M., McShane, L.M., Fabrizio, D., et al. (2020) TMB Harmonization Consortium. Establishing Guidelines to Harmonize Tumor Mutational Burden (TMB): In Silico Assessment of Variation in TMB Quantification across Diagnostic Platforms: Phase I of the Friends of Cancer Research TMB Harmonization Project. Journal for ImmunoTherapy of Cancer, 8, e000147. [Google Scholar] [CrossRef] [PubMed]
[7] Snyder, A., Makarov, V., Merghoub, T., et al. (2014) Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. The New England Journal of Medicine, 371, 2189-2199. [Google Scholar] [CrossRef] 
[8] Ang, C., Klempner, S.J., Ali, S.M., et al. (2019) Prevalence of Established and Emerging Biomarkers of Immune Checkpoint Inhibitor Response in Advanced Hepatocellular Carcinoma. Oncotarget, 10, 4018-4025. [Google Scholar] [CrossRef] [PubMed]
[9] Li, L., Rao, X., Wen, Z., et al. (2020) Implications of Driver Genes Associated with a High Tumor Mutation Burden Identified Using Next-Generation Sequencing on Immunotherapy in Hepatocellular Carcinoma. Oncology Letters, 19, 2739-2748. [Google Scholar] [CrossRef] [PubMed]
[10] Mauriello, A., Zeuli, R., Cavalluzzo, B., et al. (2019) High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients Not Undergoing Immunotherapy. Cancers, 11, Article No. 1824. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, X. and Li, M. (2019) Correlate Tumor Mutation Burden with Immune Signatures in Human Cancers. BMC Immunology, 20, Article No. 4. [Google Scholar] [CrossRef] [PubMed]
[12] Wang, S., Shi, H.S., Liu, T., et al. (2021) Mutation Profile and Its Correlation with Clinicopathology in Chinese Hepatocellular Carcinoma Patients. Hepatobiliary Surgery and Nutrition, 10, 172-179.
[13] Tang, X., Fan, L., Chen, G., Guo, W., Qiu, F., Wang, J., et al. (2018) Higher Level of Tumor Mutational Burden and 11q13 Amplification in Chinese Hepatocellular Carcinoma Patients. Cancer Research, 78, 4349. [Google Scholar] [CrossRef] 
[14] Wong, C.N., Fessas, P., Dominy, K., et al. (2021) Qualification of Tumour Mutational Burden by Targeted Next-Generation Sequencing as a Biomarker in Hepatocellular Carcinoma. Liver International, 41, 192-203.
[15] Zhou, W., Fang, D., He, Y. and Wei, J. (2021) Correlation Analysis of Tumor Mutation Burden of Hepatocellular Carcinoma Based on Data Mining. Journal of Gastrointestinal Oncology, 12, 1117-1131.
[16] Liu, S., Tang, Q., Huang, J., Zhan, M., Zhao, W., Yang, X., Li, Y., Qiu, L., Zhang, F., Lu, L. and He, X. (2021) Prognostic Analysis of Tumor Mutation Burden and Immune Infiltration in Hepatocellular Carcinoma Based on TCGA Data. Aging, 13, 11257-11280. [Google Scholar] [CrossRef] [PubMed]
[17] Xie, C., Wu, H.W., Pan, T., et al. (2021) A Novel Panel Based on Immune Infiltration and Tumor Mutational Burden for Prognostic Prediction in Hepatocellular Carcinoma. Aging, 13, 8563-8587. [Google Scholar] [CrossRef] [PubMed]
[18] Xu, Q.H., Xu, H., Deng, R.S., et al. (2021) Multi-Omics Analysis Reveals Prognostic Value of Tumor Mutation Burden in Hepatocellular Carcinoma. Cancer Cell Internatinal, 21, Article No. 342. [Google Scholar] [CrossRef] [PubMed]
[19] Dhanasekaran, R., Nault, J.C., Roberts, L.R., et al. (2019) Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 156, 492-509. [Google Scholar] [CrossRef] [PubMed]
[20] Zhu, A.X., Finn, R.S., Edeline, J., et al. (2018) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Nonrandomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952. [Google Scholar] [CrossRef] 
[21] Cheng, A.L., Hsu, C., Chan, S.L., et al. (2020) Challenges of Combination Therapy with Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Journal of Hepatology, 72, 307-319. [Google Scholar] [CrossRef] [PubMed]
[22] Yang, H.Y., Sun, L.J., Guan, A., et al. (2021) Unique TP53 Neoantigen and the Immune Microenvironment in Long-Term Survivors of Hepatocellular Carcinoma. Cancer Immunology, Immunotherapy, 70, 667-677. [Google Scholar] [CrossRef] [PubMed]
[23] Xu, J., Zhang, Y., Jia, R., et al. (2019) Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-Label, Dose Escalation and Expansion Study. Clinical Cancer Research, 25, 515-523. [Google Scholar] [CrossRef] 
[24] Chan, T.A., Yarchoan, M., Jaffee, E., et al. (2019) Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. Annals of Oncology, 30, 44-56. [Google Scholar] [CrossRef] [PubMed]
[25] Cai, H., Zhang, Y., Zhang, H., Cui, C., Li, C. and Lu, S. (2020) Prognostic Role of Tumor Mutation Burden in Hepatocellular Carcinoma after Radical Hepatectomy. Journal of Surgical Oncology, 121, 1007-1014. [Google Scholar] [CrossRef] [PubMed]
[26] Shrestha, R., Prithviraj, P., Anaka, M., et al. (2018) Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Frontiers in Oncology, 8, Article No. 269. [Google Scholar] [CrossRef] [PubMed]
[27] Yin, L., Zhou, L.Z. and Xu, R.J. (2020) Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis. Frontiers in Molecular Biosciences, 7, Article ID: 599142. [Google Scholar] [CrossRef] [PubMed]
[28] Fernandez, E.M., Eng, K., Beg, S., et al. (2019) Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-Based Tumor Mutational Burden Distribution. JCO Precision Oncology, 3, 1-12. [Google Scholar] [CrossRef] 

为你推荐